Ascendis Pharma grants 31,250 employee warrants

Ascendis Pharma A/S granted new equity incentives to employees.

Rhea-AI Filing Summary

Ascendis Pharma A/S granted new equity incentives to employees. On May 12, 2026, the board approved 31,250 warrants for certain employees under Appendix 1a of the Articles of Association. Each warrant allows purchase of one ordinary share at an exercise price of US $237.65, the closing share price on the grant date.

Twenty‑five percent of the warrants vest one year after grant, with the remaining 75% vesting in equal monthly installments over the following 36 months, subject to continued service and potential earlier vesting upon certain exit events. After this grant, warrants to subscribe for an additional 1,580,593 shares remain available for future grants under the Articles of Association.

Key Figures

Warrants granted: 31,250 warrants Exercise price: US $237.65 per share Remaining warrant capacity: 1,580,593 shares +2 more

5 metrics

Warrants granted 31,250 warrants Granted to certain employees on May 12, 2026

Exercise price US $237.65 per share Equal to closing price on grant date

Remaining warrant capacity 1,580,593 shares Warrants available for future grants after this issuance

Initial vesting tranche 25% of warrants Vest on first anniversary of grant date

Subsequent vesting schedule 75% over 36 months Vest monthly starting one year after grant, subject to service

Key Terms

Form 6-K, warrants, Articles of Association, exercise price, +1 more

5 terms

Form 6-K regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

warrants financial

"granted an aggregate of 31,250 warrants to certain employees of the Company"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

Articles of Association regulatory

"under the terms of Appendix 1a to the Company’s Articles of Association"

A company's articles of association are its written rulebook that sets how the business is run, how decisions are made, and what rights owners and directors have—covering voting, meetings, appointment and removal of directors, share classes and dividend policies. For investors, these rules matter because they determine how easily control can change, what protections minority owners have, and how corporate actions (like issuing new shares or changing leadership) are approved, much like a home’s bylaws shaping what residents can and cannot do.

exercise price financial

"has an exercise price equal to US $237.65 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"25% of the Warrants will vest on the one year anniversary of the date of grant"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ascendis Pharma (ASND) announce in this Form 6-K?

Ascendis Pharma disclosed that its board granted 31,250 new warrants to certain employees. Each warrant gives the right to buy one ordinary share, aligning employee compensation with shareholder value through equity-based incentives governed by the company’s Articles of Association.

What is the exercise price of Ascendis Pharma’s newly granted warrants?

The newly granted warrants have an exercise price of US $237.65 per share. This price equals the closing market price of Ascendis Pharma’s ordinary shares on the May 12, 2026 grant date, tying the option cost directly to the prevailing share value.

How do the Ascendis Pharma employee warrants vest over time?

Twenty-five percent of the warrants vest on the one-year anniversary of the May 12, 2026 grant. The remaining 75% then vest in equal 1/36th monthly installments over the following three years, subject to continued service and potential earlier vesting upon specified exit events.

How many additional Ascendis Pharma warrants remain available for future grants?

After this grant, warrants to subscribe for an additional 1,580,593 Ascendis Pharma shares remain available. These can be granted in the future by the board of directors under the company’s Articles of Association as part of ongoing equity incentive programs.

What corporate document governs the new Ascendis Pharma warrant grants?

The warrants were granted under Appendix 1a of Ascendis Pharma’s Articles of Association. In connection with these grants, the company amended its Articles of Association, which are included as Exhibit 1.1 and incorporated by reference in the Form 6-K.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/13/2026 - 04:05 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May, 2026

Commission File Number: 001-36815

Ascendis Pharma A/S

(Translation of registrant’s name into English)

Tuborg Boulevard 12

DK-2900 Hellerup

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-228576, 333-254101, 333-261550, 333-270088, 333-277519, 333-281916, 333-285322 and 333-293854) and Form F-3 (Registration Numbers 333-209336 and 333-282196) of Ascendis Pharma A/S (the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Warrant Grants

On May 12, 2026, the Company’s board of directors granted an aggregate of 31,250 warrants to certain employees of the Company (the “Warrants”) under the terms of Appendix 1a to the Company’s Articles of Association. In connection with the grant of these Warrants, the Company amended its Articles of Association to provide for the grant of these Warrants. Each Warrant confers the right to subscribe for one ordinary share of the Company and has an exercise price equal to US $237.65 per share, the closing price of the Company’s ordinary shares as reported on the date of grant. Subject to earlier vesting upon the occurrence of certain exit events, 25% of the Warrants will vest on the one year anniversary of the date of grant and the remaining 75% will vest at a rate of 1/36th per month from one year after the date of grant, subject to continued service.

After giving effect to the grant of the Warrants described above, warrants to subscribe for an additional 1,580,593 shares of the Company remain available for future grant by the Company’s board of directors pursuant to the Company’s Articles of Association. The foregoing description of the material terms of the Warrants is qualified in its entirety by reference to the Company’s Articles of Association, which is included as Exhibit 1.1 hereto and incorporated by reference herein.

Exhibits

Exhibit No.		Description
1.1		Articles of Association.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Ascendis Pharma A/S
Date: May 13, 2026				By:		/s/ Michael Wolff Jensen
						Michael Wolff Jensen
						Executive Vice President, Chief Legal Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-1.1 EX-1.1 500.3 KB